CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Canada's Aurora Cannabis Q2 revenue beats estimates on international demand

By Reuters News


Overview

  • Canada medical cannabis producer's fiscal Q2 revenue rose 9% yr/yr, beating analyst expectations

  • Adjusted net income for fiscal Q2 declined yr/yr

  • Company to be acquired by Organigram in deal expected to close January 2027


Outlook

  • Aurora Cannabis expects acquisition by Organigram to close in January 2027, pending approvals


Result Drivers

  • INTERNATIONAL MEDICAL SALES - Co said record international medical cannabis net revenue rose 44% yr/yr, mainly due to higher sales in Germany and Poland driven by increased patient demand

  • CANADIAN MEDICAL REIMBURSEMENT CHANGES - Co said Canadian medical cannabis net revenue fell 24% yr/yr, mainly due to changes in the federal reimbursement program effective April 1, 2026

  • CONSUMER CANNABIS WIND DOWN - Co said consumer cannabis net revenue dropped due to its strategic shift to focus on medical cannabis and wind down its consumer cannabis business


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

C$86.02 mln

C$72.17 mln (6 Analysts)

Q2 Adjusted Net Income

C$3.11 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Aurora Cannabis Inc. is C$7.80, about 6.7% above its November 4 closing price of C$7.31


Reuters Recommended Reads

  • Nov 4 - Green Thumb Q3 revenue beats estimates on retail, CPG growth

  • Nov 4 - Canada's Kinaxis Q3 SaaS revenue rises, lifts 2026 outlook

  • Nov 4 - Canada's Sun Life Q3 adjusted EPS beats estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.